دورية أكاديمية
Adipose-Derived Mesenchymal Stem Cells Prevent Systemic Bone Loss in Collagen-Induced Arthritis.
| العنوان: | Adipose-Derived Mesenchymal Stem Cells Prevent Systemic Bone Loss in Collagen-Induced Arthritis. |
|---|---|
| المؤلفون: | Garimella MG; National Centre for Cell Science, Ganeshkhind, Pune 411 007, India; and., Kour S; National Centre for Cell Science, Ganeshkhind, Pune 411 007, India; and., Piprode V; National Centre for Cell Science, Ganeshkhind, Pune 411 007, India; and., Mittal M; Division of Endocrinology, Council of Scientific and Industrial Research-Central Drug Research Institute, Lucknow 226 031, India., Kumar A; National Centre for Cell Science, Ganeshkhind, Pune 411 007, India; and., Rani L; National Centre for Cell Science, Ganeshkhind, Pune 411 007, India; and., Pote ST; National Centre for Cell Science, Ganeshkhind, Pune 411 007, India; and., Mishra GC; National Centre for Cell Science, Ganeshkhind, Pune 411 007, India; and., Chattopadhyay N; Division of Endocrinology, Council of Scientific and Industrial Research-Central Drug Research Institute, Lucknow 226 031, India., Wani MR; National Centre for Cell Science, Ganeshkhind, Pune 411 007, India; and mohanwani@nccs.res.in. |
| المصدر: | Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2015 Dec 01; Vol. 195 (11), pp. 5136-48. Date of Electronic Publication: 2015 Nov 04. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association of Immunologists Country of Publication: United States NLM ID: 2985117R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1550-6606 (Electronic) Linking ISSN: 00221767 NLM ISO Abbreviation: J Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Bethesda, MD : American Association of Immunologists Original Publication: Baltimore : Williams & Wilkins, c1950- |
| مواضيع طبية MeSH: | Arthritis, Experimental/*immunology , Arthritis, Rheumatoid/*immunology , Bone Resorption/*immunology , Mesenchymal Stem Cells/*immunology , Osteoclasts/*immunology , RANK Ligand/*antagonists & inhibitors, Adipose Tissue/cytology ; Animals ; Arthritis, Experimental/pathology ; Arthritis, Rheumatoid/pathology ; Autoimmunity/immunology ; B-Lymphocytes/immunology ; Bone and Bones/immunology ; Bone and Bones/pathology ; Cell Differentiation/immunology ; Cell Proliferation ; Cells, Cultured ; Disease Models, Animal ; Female ; Immune Tolerance/immunology ; Interleukin-17/metabolism ; Interleukin-1beta/metabolism ; Lymphocyte Count ; Male ; Mice ; Mice, Inbred DBA ; T-Lymphocytes, Regulatory/immunology ; Tumor Necrosis Factor-alpha/metabolism |
| مستخلص: | Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammatory synovitis leading to joint destruction and systemic bone loss. The inflammation-induced bone loss is mediated by increased osteoclast formation and function. Current antirheumatic therapies primarily target suppression of inflammatory cascade with limited or no success in controlling progression of bone destruction. Mesenchymal stem cells (MSCs) by virtue of their tissue repair and immunomodulatory properties have shown promising results in various autoimmune and degenerative diseases. However, the role of MSCs in prevention of bone destruction in RA is not yet understood. In this study, we investigated the effect of adipose-derived MSCs (ASCs) on in vitro formation of bone-resorbing osteoclasts and pathological bone loss in the mouse collagen-induced arthritis (CIA) model of RA. We observed that ASCs significantly inhibited receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis in both a contact-dependent and -independent manner. Additionally, ASCs inhibited RANKL-induced osteoclastogenesis in the presence of proinflammatory cytokines such as TNF-α, IL-17, and IL-1β. Furthermore, treatment with ASCs at the onset of CIA significantly reduced clinical symptoms and joint pathology. Interestingly, ASCs protected periarticular and systemic bone loss in CIA mice by maintaining trabecular bone structure. We further observed that treatment with ASCs reduced osteoclast precursors in bone marrow, resulting in decreased osteoclastogenesis. Moreover, ASCs suppressed autoimmune T cell responses and increased the percentages of peripheral regulatory T and B cells. Thus, we provide strong evidence that ASCs ameliorate inflammation-induced systemic bone loss in CIA mice by reducing osteoclast precursors and promoting immune tolerance. (Copyright © 2015 by The American Association of Immunologists, Inc.) |
| References: | J Bone Miner Res. 2009 Sep;24(9):1572-85. (PMID: 19338457) Ann Rheum Dis. 2013 Jan;72(1):1-2. (PMID: 23172746) Clin Immunol. 2011 Dec;141(3):328-37. (PMID: 21944669) J Immunol. 2003 Jul 1;171(1):142-51. (PMID: 12816992) Science. 2000 Sep 1;289(5484):1504-8. (PMID: 10968780) Immunol Cell Biol. 2013 Jan;91(1):19-26. (PMID: 23090487) Cell Mol Immunol. 2013 Mar;10(2):122-32. (PMID: 23292280) J Immunol. 2010 Jun 15;184(12):7238-46. (PMID: 20483756) Diabetes. 2015 Jul;64(7):2609-23. (PMID: 25633418) Arthritis Res Ther. 2010;12(1):R31. (PMID: 20175883) Ann Rheum Dis. 2009 May;68(5):744-50. (PMID: 18480308) Acta Pharmacol Sin. 2013 Jun;34(6):747-54. (PMID: 23736003) Arthritis Rheum. 2011 Jun;63(6):1668-80. (PMID: 21384335) Nature. 2002 Jul 4;418(6893):41-9. (PMID: 12077603) PLoS One. 2013;8(8):e72831. (PMID: 23940819) Arthritis Rheum. 2005 Jul;52(7):2212-21. (PMID: 15986351) Clin Exp Immunol. 2008 Aug;153(2):269-76. (PMID: 18713142) Curr Opin Rheumatol. 2006 Jul;18(4):411-8. (PMID: 16763463) J Immunol. 2009 Jan 1;182(1):361-70. (PMID: 19109167) Br J Pharmacol. 2012 Mar;165(5):1526-42. (PMID: 21864313) Nat Rev Rheumatol. 2012 Nov;8(11):656-64. (PMID: 23007741) Stem Cells Dev. 2009 Dec;18(10):1473-84. (PMID: 19374589) Arthritis Rheum. 2011 Jun;63(6):1658-67. (PMID: 21360521) Transplant Proc. 2008 Oct;40(8):2649-54. (PMID: 18929828) Autoimmun Rev. 2007 Nov;7(1):65-70. (PMID: 17967728) J Bone Miner Res. 2010 Jul;25(7):1468-86. (PMID: 20533309) Biochem Biophys Res Commun. 2010 Mar 12;393(3):377-83. (PMID: 20138833) Neuroimmunomodulation. 2013;20(5):294-303. (PMID: 23899693) J Immunol. 2011 May 15;186(10):5569-79. (PMID: 21464089) Arthritis Rheum. 2007 Apr;56(4):1175-86. (PMID: 17393437) Cell. 2008 May 30;133(5):775-87. (PMID: 18510923) Autoimmun Rev. 2013 Aug;12(10):958-66. (PMID: 23542506) Nature. 2003 May 15;423(6937):356-61. (PMID: 12748655) J Immunol. 2007 Jul 15;179(2):1369-80. (PMID: 17617630) Arthritis Rheum. 2009 Apr;60(4):1006-19. (PMID: 19333946) J Clin Invest. 2008 Oct;118(10):3420-30. (PMID: 18802481) Cell Res. 2010 May;20(5):510-8. (PMID: 20368733) Science. 1999 Apr 2;284(5411):143-7. (PMID: 10102814) J Hematol Oncol. 2012;5:19. (PMID: 22546280) Arthritis Rheum. 2005 May;52(5):1595-603. (PMID: 15880818) Clin Exp Immunol. 2014 Feb;175(2):172-80. (PMID: 24028747) Int J Endocrinol. 2013;2013:213234. (PMID: 23573086) Nat Rev Immunol. 2007 Jun;7(6):429-42. (PMID: 17525752) Stem Cells Int. 2012;2012:461718. (PMID: 22666271) Arthritis Rheum. 2013 May;65(5):1181-93. (PMID: 23400582) Endocrinology. 1999 Aug;140(8):3736-43. (PMID: 10433234) Osteoarthritis Cartilage. 2009 Jun;17(6):735-42. (PMID: 19136283) |
| المشرفين على المادة: | 0 (IL1B protein, mouse) 0 (Interleukin-17) 0 (Interleukin-1beta) 0 (RANK Ligand) 0 (Tnfsf11 protein, mouse) 0 (Tumor Necrosis Factor-alpha) |
| تواريخ الأحداث: | Date Created: 20151106 Date Completed: 20160315 Latest Revision: 20181202 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC4654226 |
| DOI: | 10.4049/jimmunol.1500332 |
| PMID: | 26538398 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1550-6606 |
|---|---|
| DOI: | 10.4049/jimmunol.1500332 |